Reported Sunday, Summit Announces Ivonescimab Achieved Median Progression-Free Survival Of 11.14 Months Compared To 6.90 Months For Tislelizumab Plus Chemotherapy In Landmark HARMONi-6 Trial

Author: Benzinga Newsdesk | October 20, 2025 02:16am

• Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in 1L NSCLC: Median PFS of 11.14 Months vs. 6.90 Months, Respectively, for Patients Receiving Ivonescimab Plus Chemotherapy vs. Tislelizumab Plus Chemotherapy; Hazard Ratio of 0.60
• Tolerable Safety Profile Reaffirmed for PD-1 / VEGF Bispecific in Squamous NSCLC: Comparable Serious Treatment-Related Adverse Events and TRAE-Led Discontinuation & Death Rates Were Observed in the Two Arms of HARMONi-6
• Summit-Sponsored HARMONi-3 Global Study Will be Split into Two Analyses by Histology: Squamous NSCLC Cohort Expected to Complete Enrollment in First Half 2026 with Data Readout Expected in Second Half 2026; Non-Squamous NSCLC Cohort Expected to Complete Enrollment in Second Half 2026
• Simultaneous Ivonescimab Manuscript for HARMONi-6 Clinical Trial Results Published in The Lancet
• Conference Call to be Held at 8:00am ET on Monday, October 20, 2025

Posted In: SMMT